Abstract
In 2018, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: bictegravir, emtricitabine, and tenofovir alafenamide (Biktarvy); doxylamine succinate and pyridoxine hydrochloride (Bonjesta); erenumab-aooe (Aimovig); lofexidine hydrochloride (Lucemyra); tezacaftor and ivacaftor (Symdeko); and tildrakizumab-asmn (Ilumya).
MeSH terms
-
Adenine / analogs & derivatives
-
Adenine / therapeutic use
-
Alanine
-
Amides
-
Aminophenols / therapeutic use
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Benzodioxoles / therapeutic use
-
Clonidine / analogs & derivatives
-
Clonidine / therapeutic use
-
Doxylamine / analogs & derivatives
-
Doxylamine / therapeutic use
-
Drug Approval*
-
Emtricitabine / therapeutic use
-
Heterocyclic Compounds, 3-Ring
-
Heterocyclic Compounds, 4 or More Rings / therapeutic use
-
Humans
-
Indoles / therapeutic use
-
Piperazines
-
Pyridones
-
Pyridoxine / therapeutic use
-
Quinolones / therapeutic use
-
Tenofovir / analogs & derivatives
-
United States
-
United States Food and Drug Administration*
Substances
-
Amides
-
Aminophenols
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Benzodioxoles
-
Heterocyclic Compounds, 3-Ring
-
Heterocyclic Compounds, 4 or More Rings
-
Indoles
-
Piperazines
-
Pyridones
-
Quinolones
-
tezacaftor
-
ivacaftor
-
bictegravir
-
Doxylamine
-
Tenofovir
-
tildrakizumab
-
tenofovir alafenamide
-
Emtricitabine
-
erenumab
-
Adenine
-
Pyridoxine
-
Clonidine
-
Alanine
-
lofexidine
-
doxylamine succinate